DxM MicroScan WalkAway System

Detect antimicrobial resistance with proven expertise

The DxM MicroScan WalkAway microbiology system delivers trusted detection of emerging and critical antimicrobial resistance with gold-standard1 MIC accuracy. Designed with ease of use as a focal point, this bacterial identification and antimicrobial susceptibility testing (ID/AST) system provides streamlined workflows and enhanced performance compared to its predecessors.2 The DxM MicroScan WalkAway system continues the legacy of innovation and high-quality products you have trusted for 40 years. Enable your laboratory to optimize patient care while reducing risks, costs and operational burden associated with detecting emerging antimicrobial resistance.

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Detect Antimicrobial Resistance with Proven Expertise

Learn how the DxM MicroScan WalkAway system can benefit your microbiology laboratory. 

Discover the Speed and Accuracy of MALDI-TOF

Explore the history of MALDI-TOF and its applications for advancing antimicrobial stewardship.

Discover the right MicroScan Panels for Your Lab

Your antimicrobial testing needs are unique. Our MicroScan Panel GuIDe helps ensure you get the right solution for your laboratory. Choose the antibiotics, Gram and panel types that support your specific formulary. Our specially designed tool will quickly identify the MicroScan panel options that best meet your criteria.

ID/AST Test Results Done Right with DxM MicroScan WalkAway System

In the detection of infectious disease, speed and accuracy are key, but pathologists shouldn’t have to choose between the two. Find out how one laboratory is optimizing patient care by rapidly and accurately identifying organisms while testing over 30,000 specimens per year.

Antibiotic Stewardship: The Basics for U.S. Microbiologists

Learn about the basics of antibiotic stewardship as it applies to U.S. microbiologists. In this webinar, Barbara Zimmer, Ph.D., will explore solutions to the challenges laboratories face in combating emerging antibiotic resistance in today’s laboratory.


1Kalorama United States Market for In Vitro Diagnostic Tests, 2017, pg. 878.
2Reference applicable Procedural Manuals for performance characteristics and limitations. Refer to publications for evaluation of performance with emerging resistance.
3ServiceTrak™ Clinical Executive Summary Report for ID/AST Systems, 2019.
4Bulik CC et al. J Clin Microbiol. 2010 July; 48(7): 2402–2406.
5Anderson KF et al. J Clin Microbiol. 2007 August; 45(8): 2723–2725.
6Woodford N et al. J Clin Microbiol. 2010 August; 48(8): 2999–3002.
7The assessment of clinically significant limitations is based upon a tabulation of CLSI Group A and B test and report recommendations published in the M100 guidance documents (excluding species with natural resistance) and 1st and 2nd drugs of choice published in The Medical Letter‘s Handbook of Antimicrobial Therapy, compared with the related FDA 510K summaries, device manufacturer‘s package inserts and product recall information. M100-S17, 2017.
8ServiceTrak™ Clinical Executive Summary Report for ID/AST Systems, 2016.

WASP is a registered trademark or trademark of Copan Italia SpA.
MALDI Biotyper is the property of Bruker Daltonik GmbH.
Prompt is a registered trademark of 3M.